Vericel Nasdaq:VCEL Stock Price, News & Analysis

We have upgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Buy candidate. Real-time analyst ratings, insider transactions, earnings data, and more. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 to -2 . This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.

Prudential Financial Inc. now owns 50,834 shares of the biotechnology company’s stock worth $1,208,000 after buying an additional 768 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Vericel by 1.0% in the second quarter. Legal & General Group Plc now owns 110,238 shares of the biotechnology company’s stock valued at $2,776,000 after buying an additional 1,088 shares during the period. Finally, LPL Financial LLC boosted its stake in Vericel by 6.1% during the second quarter. LPL Financial LLC now owns 19,636 shares of the biotechnology company’s stock valued at $494,000 after buying an additional 1,126 shares in the last quarter.

share page

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. Stocks are for suckers – try this insteadThis has nothing to do with dividends, day trading… What you need is about 3 seconds to execute this simple financial maneuver… Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat’s FREE daily newsletter.

According to 0 prominent analysts, Vericel’s EBITDA will fall by 53.48% in the next year, reaching $-5.41M. By 2030, professionals believe that Vericel’s EBITDA will decrease by 4.19%, reaching $-11.15M – a concerning trend for the company. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. 3.02% during the next 3 months and, with a 90% probability hold a price between $29.14 and $33.01 at the end of this 3-month period. Vericel Corporation stock upgraded from Hold/Accumulate to Buy Candidate after Monday trading session.

Chief Medical Officer notifies of intention to sell stock

One share of VCEL stock can currently be purchased for approximately $30.50. The P/E ratio of Vericel is -84.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Vericel has only been the subject of 2 research reports in the past 90 days.

BTIG analyst Ryan Zimmerman maintained a Hold rating on Vericel (VCEL – Research Report) today. The company’s shares closed yesterday at $23.54.Zimmerman covers the Healthcare sector, focusing on stocks such as Medtronic, … A valuation method that multiplies the price of a company’s stock by the total number of outstanding shares. While Vericel currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys. Vericel Corporation delivered earnings and revenue surprises of -16.67% and 3.68%, respectively, for the quarter ended September 2022. Vericel Corporation focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions.

Stock , VCEL

Market Cap is calculated by multiplying the number of shares outstanding by the stock’s price. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.Dividend YieldA company’s dividend expressed as a percentage of its current stock price. Several equities research analysts have recently weighed in on VCEL shares. Truist Financial increased their price objective on Vericel from $29.00 to $31.00 and gave the company a “hold” rating in a research report on Monday, February 27th. HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Vericel in a research report on Friday, January 27th.

• Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
• HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Vericel in a research report on Friday, January 27th.
• Zacks Ranks stocks can, and often do, change throughout the month.
• Several other large investors have also modified their holdings of the company.

According to analysts’ consensus price target of $35.50, Vericel has a forecasted upside of 16.4% from its current price of $30.50. The company’s average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings. Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months.

We what is the most secure funding different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.

Captrust Financial Advisors increased its stake in shares of Vericel by 50.8% in the second quarter. Captrust Financial Advisors now owns 3,486 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 1,175 shares during the period. Boosted its stake in Vericel by 2,800.0% during the 3rd quarter. Now owns 4,466 shares of the biotechnology company’s stock valued at $103,000 after purchasing an additional 4,312 shares during the period. Finally, Advisors Asset Management Inc. grew its holdings in Vericel by 6.7% in the 3rd quarter. Advisors Asset Management Inc. now owns 7,197 shares of the biotechnology company’s stock valued at $167,000 after buying an additional 452 shares during the last quarter.

Finally, HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of Vericel in a report on Friday, January 27th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $35.50. 4 Wall Street analysts have issued 12 month price targets for Vericel’s shares. Their VCEL share price forecasts range from $31.00 to $40.00.

8 people have searched for VCEL on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. MarketBeat has tracked 2 news articles for Vericel this week, compared to 2 articles on an average week. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Upgrade to MarketBeat All Access to add more stocks to your watchlist.

In a similar fashion, Vericel Corporation posted a movement of +34.23% for the period of last 100 days, recording 401,582 in trading volumes. Vericel’s stock is projected to advance by 63.93% from the previous closing price if it reaches the average target of $50.00 by the year’s end, as reputable analysts recently projected. This potential upside is calculated on a high-end estimate of $53.00 and a low-end estimate of $34.00. If you’re interested in VCEL stock, it’s important to compare it to other companies in the industry. On corrections down, there will be some support from the lines at $29.37 and $29.72.

There may be delays, omissions, or inaccuracies in the Information. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Vericel Corporation finds support from accumulated volume at $29.54 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

According a new https://1investing.in/ published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. At the end of the latest market close, Vericel Corporation was valued at $29.00. In that particular session, Stock kicked-off at the price of $29.25 while reaching the peak value of $30.14 and lowest value recorded on the day was $28.71.

Commonwealth Equity Services LLC increased its position in shares of Vericel by 6.9% during the 3rd quarter. Commonwealth Equity Services LLC now owns 9,986 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 644 shares during the period. Prudential Financial Inc. raised its stake in shares of Vericel by 1.5% in the 3rd quarter.